Skip to content
Molecules
SEKISUI XenoTech DD Blog Logo

Author: Michael Millhollen

Why Switch to Hepatocyte Pellets?

You may have heard about the patented CryostaX® format of hepatocyte pellets, but do you know why SEKISUI XenoTech and countless other researchers have made…

Meet the Scientist: Shanté Jackson

Shanté is a Research Scientist who joined SXT in 2017 and serves as a Drug Inhibition and Drug Metabolism Study Director and Drug Transport Lead…

SEKISUI XenoTech Named Most Innovative Drug Development Solutions Provider – USA 2020

The 2020 Technology Innovator Awards returns for its fifth year “to reward those talented and dedicated individuals and firms working...

Who is SEKISUI America?

We pride ourselves on providing cutting edge science for the betterment of humankind, but we’re not the only one. SEKISUI...

COVID-19 Updates

As a global Life Sciences and Healthcare company, SEKISUI XenoTech recognizes the seriousness of the Coronavirus Pandemic. We are constantly...

Meet the Scientist: Andrea Wolff

At SEKISUI, we pride ourselves on our 3S Principles ­– the values and standards that guide our businesses and shape...

SEKISUI CHEMICAL selected as one of the 2020 Global 100 Most Sustainable Corporations in the World for the Third Year Running

SEKISUI CHEMICAL CO., LTD. (President and Representative Director: Teiji Koge; hereinafter, “SEKISUI CHEMICAL”) has been selected as one of the...

Meet the Scientist: Mark Horrigan

Continuing our effort to put faces to the names of some of the scientists you interact with at SEKISUI XenoTech,...

Meet the Scientist: Rachel Murphy, PhD

We thought it might be nice to put faces to the names of some of the scientists you interact with...

SEKISUI XenoTech Named Best In Vitro Drug CRO 2019

SEKISUI XenoTech has been named the Best In Vitro Drug CRO in the 2019 Healthcare & Pharmaceutical Awards. From the...

SEKISUI XenoTech Named a 2019 Top-Performing Provider on Science Exchange

Science Exchange stated, “Discovery research programs at growing biotech companies are demanding—R&D leaders must balance the need to innovate with...

SEKISUI XenoTech Named Best for Drug Candidate Evaluations 2019, Leading Providers of Pharmaceuticals Safety Testing

SEKISUI XenoTech has been named the Best for Drug Candidate Evaluations 2019 as well as in the Leading Providers of...

Disease-State Test Systems

SEKISUI XenoTech has been working with and supplying reagents for the pre-clinical ADME field for well over two decades. Years...

5 Keys to Set Your Contract Research Organization (CRO) Collaboration Up for Success

Over the past 25 years of performing ADME/DMPK/DDI contract research, we’ve learned some key strategies to maximize the efficiency and effectiveness...

Holiday CSR Activities

SEKISUI understands that a better future starts with our actions today, and encourages its global family to remain focused on...

SEKISUI Continues Environmental Awareness

SEKISUI at Natural Capital Week in Paris On Wednesday 28th November, the Natural Capital Coalition: Collaboration Day took place in...

October Presentations on In Vitro Effects of Biologics on CYP Enzymes and Regulatory DDI Guidances

On Oct. 15th at the Peptide ADME Discussion Group Workshop in Gothenburg, Sweden, Dr. Brian Ogilvie presented on In vitro Direct and Cytokine-Mediated...

New Rodent, Monkey CryostaX Hepatocytes Featured in Industry News

Following SEKISUI XenoTech’s announcement SEKISUI XenoTech Adds Monkey, Rodent Hepatocytes to Patented CryostaX Product Line, Anticipates the End of Traditionally Cryopreserved...

Challenges & Solutions in Today’s In Vitro Transporter Research

Transporters are membrane-bound proteins that govern the passage of drugs into and out of cells. These gatekeeper proteins can be...

SEKISUI XenoTech Named Best Global CRO 2018; Recognised Leaders in Pharmaceutical Safety Testing 2018

SEKISUI XenoTech has been named the Best Global CRO and was recognized for leadership in Pharmaceutical Safety Testing in the...

Response to FDA Framework for Assessment of Drug-Drug Interactions for Therapeutic Proteins RFI and Comments

In July, Drs. Maciej Czerwinski, Director of Consulting, and Brian Ogilvie, Vice President of Scientific Consulting, submitted SEKISUI XenoTech’s comments in response to the...

No-Cost, On-Demand Primary Human Hepatocyte Pooling Using CryostaX Pellets

CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets. This format allows scientists to easily pool primary...

In Vitro DDI Regulatory Guidance Reference Poster

At the 2018 Marbach Castle Drug-Drug Interaction Workshop in Germany, Dr. Brian Ogilvie, Vice President of Scientific Consulting, presented a comparison...

Maximize Metabolic Activities by Limiting Hepatocyte Cryoinjury

Cryopreservation and thawing of primary hepatocytes causes inherent damage to the cells. Traditional pooling methods require cells to undergo two separate cryopreservation...

No More Water Baths! Simplify Hepatocyte Thaws and Eliminate Contamination

SEKISUI XenoTech has patented technology that eliminates the need for the water baths that are traditionally required to thaw cryopreserved hepatocytes. By removing...

SEKISUI XenoTech Adds US and Japanese Support for MATE1 and MATE2-K Drug Transporter Studies

Transporters have become increasingly important in drug development due to the major role they play in absorption, distribution and excretion of...

SEKISUI Medical Celebrates its 10th Anniversary

In 2006, Daiichi Pure Chemicals Co., Ltd. was acquired by SEKISUI Chemical Co., Ltd. In April of 2008, SEKISUI Medical...

SEKISUI XenoTech Named Best In Vitro Drug Metabolism Studies Provider 2018

Following our nomination in late 2017, SEKISUI XenoTech has been named the Best In Vitro Drug Metabolism Studies Provider in...

Insects and Cattle and Sheep, Oh My!

Over the past two decades, we’ve received a lot of interesting requests for custom tissue preparations here at SEKISUI XenoTech....

SEKISUI Named in the 2018 Global 100 World’s Most Sustainabl

SEKISUI CHEMICAL CO., LTD. announced that it has been selected as one of the 2018 Global 100 Most Sustainable Corporations in the...

SEKISUI XenoTech Hiring and Growing to Meet Customer Demand

As announced earlier this month, SEKISUI XenoTech has hired a record number of new staff over the past year in order...

SEKISUI XenoTech Featured in Fall Issue of NewsWave

Leader in pharmaceutical research and scientific collaboration Originally printed in the Fall 2017 Issue of NewsWave. SEKISUI XenoTech, LLC, which...

Initial Impressions of New Draft FDA DDI Guidance Documents from SEKISUI XenoTech

Updated Nov. 6th, 2017 The FDA has released its long-awaited new draft guidance for industry on drug-drug interaction (DDI) studies....

Further Research on the Drug-Drug Interaction Between Gemfibrozil and Repaglinide Presented

The clinically-relevant drug-drug interaction (DDI) between the dyslipidemia drug gemfibrozil and the antidiabetic repaglinide is well-documented throughout the literature. In...

Cold Storage Solution Linked to Lower AO, XO Activity

At the time of organ recovery, human livers that have been donated for research are flushed with an ice-cold perfusion...

Considerations In Response to Drug-Drug Interaction Guidances

Check out the recent IQ consortium publication: Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from...

URI Drug Transporters Workshop Presentations

The University of Rhode Island College of Pharmacy’s 5th Annual Transporters in Drug Discovery and Development: Driving Knowledge from Laboratory...

New Division Directors for Core Services and Logistics

Following the promotion of Dr. Joanna Barbara, PhD, to Vice President of Scientific Operations, Dr. Etsuko Usuki, PhD, has been promoted...

SEKISUI XenoTech’s Analytical Services Department Adds Instrumentation

SEKISUI XenoTech’s Analytical Services lab provides researchers with custom method development and method validation, dose solution analysis, in vitro and in vivo metabolite profiling studies, small-molecule non-GLP...

UGT Activities, Concomitant Drugs, and DDI

If you have concerns about how your compound may affect UDP-glucuronosyltransferase (UGT) induction and/or inhibition when combined with other therapeutic...

New Liver Disease Resource and Other Research Biobank News

SEKISUI XenoTech is committed to furthering the knowledge surrounding hepatic diseases, which affects one out of four people worldwide, such...

Big Hepatocyte News!

As you may have heard, SEKISUI XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS” for its CryostaX® hepatocytes....

New VP of Scientific Operations and VP of Scientific Consulting

SEKISUI XenoTech has appointed Joanna Barbara, Ph.D., as Vice President of Scientific Operations and Brian Ogilvie, Ph.D., as Vice President...

SEKISUI XenoTech Adds New Drug Transporters to Portfolio

Transporters have become increasingly important in drug development due to the major role they play in absorption, distribution and excretion of...

SEKISUI Turns 70 This Month

From a single plastics manufacturing plant in Japan to a diverse, multi-billion-dollar, global family which includes SEKISUI XenoTech in Kansas...

SEKISUI XenoTech Named Best for Pharmaceutical Safety Testing 2017

After our nomination in late 2016, SEKISUI XenoTech has been named the Best for Pharmaceutical Safety Testing in the 2017...

SEKISUI XenoTech Adds New Dermal Subcellular Fraction Test Systems

SEKISUI XenoTech is adding human and minipig to the company’s list of species with dermal subcellular fractions available as standard test systems for the...

Pharmaceutical Outsourcing Magazine Interview Nov-Dec 2016

For their November/December 2016 issue, Pharmaceutical Outsourcing Magazine interviewed Chris Bohl, PhD, Global Technical Support Manager for SEKISUI XenoTech’s Products Division, on...

SEKISUI XenoTech Featured on Labiotech.EU

Understand which transporters are involved in a drug’s absorption, distribution & excretion Originally posted on Labiotech.EU How can you build the...

XenoTech Scientists Publish Paper, Present Research Evaluating Ketoconazole and its Alternative Clinical CYP3A4-5 Inhibitors as Inhibitors of Drug Transporters

SEKISUI XenoTech scientists published a paper in Drug Metabolism and Disposition evaluating Ketoconazole and its alternative clinical CYP3A4-5 inhibitors as inhibitors of drug...

SEKISUI XenoTech Fulfills Largest Order To Date

Sekisui XenoTech recently fulfilled its largest order of human liver subcellular fractions to date. A large pharmaceutical customer ordered over...

XenoTech Executives Take the Ice Bucket Challenge to Benefit ALS

Today, XenoTech Executives took the Ice Bucket Challenge to Benefit ALS. Challenged by XenoTech Chief Scientific Officer, Dr. David Buckley,...

Important Considerations for the Conduct of In Vitro Drug Transporter Assays

Not only can drug transporters affect the absorption and excretion of drugs, they can be involved in pharmacokinetic-based drug-drug interactions...

Coverage from the October 2018 PBSS DDI Workshop

The Pharmaceutical and BioScience Society (PBSS) hosted the workshop “Drug-Drug Interactions: Update on Risk Assessment, Clinical Evaluation and Regulatory Requirements” on October...

AAPS-FDA Drug Transporters

The American Association of Pharmaceutical Scientists (AAPS) and U.S. Food and Drug Administration (FDA) co-sponsored the workshop “Drug Transporters in ADME:...

SEKISUI XenoTech Featured in Fall Issue of NewsWave

Leader in pharmaceutical research and scientific collaboration Originally printed in the Fall 2017 Issue of NewsWave. SEKISUI XenoTech, LLC, which...

Considerations When Studying Esterase Activities in the Intestine

The gastrointestinal wall is a significant site of first-pass metabolism for oral drugs, which is commonly associated with CYP450 and...

SEKISUI XenoTech Joins Fight Against Liver Disease

SEKISUI XenoTech is committed to furthering the knowledge surrounding hepatic diseases, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic...

SEKISUI XenoTech Featured on Labiotech.EU

Understand which transporters are involved in a drug’s absorption, distribution & excretion Originally posted on Labiotech.EU How can you build the...

SEKISUI XenoTech Fulfills Largest Order To Date

Sekisui XenoTech recently fulfilled its largest order of human liver subcellular fractions to date. A large pharmaceutical customer ordered over...

XenoTech Hosts Bring Your Kids to Work Day

On Thursday, April 23rd, XenoTech participated in “bring your child to work day”. At XenoTech, we are passionate about what...

XenoTech Executives Take the Ice Bucket Challenge to Benefit ALS

Today, XenoTech Executives took the Ice Bucket Challenge to Benefit ALS. Challenged by XenoTech Chief Scientific Officer, Dr. David Buckley,...

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate